Bacterial Conjunctivitis (Ophthalmology) - Drugs In Development, 2021

July 2021 | 35 pages | ID: B149D85F1FDBEN
Global Markets Direct

Abstracts

Bacterial Conjunctivitis (Ophthalmology) - Drugs In Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bacterial Conjunctivitis - Drugs In Development, 2021, provides an overview of the Bacterial Conjunctivitis (Ophthalmology) pipeline landscape.

Bacterial conjunctivitis is an inflammation of the conjunctiva caused by pathogenic bacteria. Bacterial conjunctivitis is usually caused by Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus sp, or, less commonly, Chlamydia trachomatis. Symptoms include redness in the white of the eye or inner eyelid, itchy eyes, blurred vision, increased sensitivity to light and burning eyes. Treatment includes antibiotics.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bacterial Conjunctivitis - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Bacterial Conjunctivitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bacterial Conjunctivitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Bacterial Conjunctivitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Preclinical and Discovery stages are 4, 2 and 1 respectively.

Bacterial Conjunctivitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Bacterial Conjunctivitis (Ophthalmology).
• The pipeline guide reviews pipeline therapeutics for Bacterial Conjunctivitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Bacterial Conjunctivitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Bacterial Conjunctivitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Bacterial Conjunctivitis (Ophthalmology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Bacterial Conjunctivitis (Ophthalmology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Bacterial Conjunctivitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Bacterial Conjunctivitis - Overview
Bacterial Conjunctivitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Bacterial Conjunctivitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Bacterial Conjunctivitis - Companies Involved in Therapeutics Development
Cellics Therapeutics Inc
IACTA Pharmaceuticals Inc
Kurobe LLC
Laboratorios Sophia SA de CV
NTC srl
Takeda Pharmaceutical Co Ltd
TGV-Inhalonix Inc
Bacterial Conjunctivitis - Drug Profiles
CTI-005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IC-702 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ketorolac tromethamine + levofloxacin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Mul-1867 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pazufloxacin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SHP-640 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vancomycin hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bacterial Conjunctivitis - Dormant Projects
Bacterial Conjunctivitis - Product Development Milestones
Featured News & Press Releases
Oct 03, 2013: Lupin launches Generic ZYMAXID Ophthalmic solution in the US
Aug 28, 2013: Lupin Receives FDA Approval For Gatifloxacin Eye Drops
Jul 01, 2013: Lupin Gets FDA Tentative Approval For Gatifloxacin Eye Drops
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Bacterial Conjunctivitis, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Bacterial Conjunctivitis - Pipeline by Cellics Therapeutics Inc, 2021
Bacterial Conjunctivitis - Pipeline by IACTA Pharmaceuticals Inc, 2021
Bacterial Conjunctivitis - Pipeline by Kurobe LLC, 2021
Bacterial Conjunctivitis - Pipeline by Laboratorios Sophia SA de CV, 2021
Bacterial Conjunctivitis - Pipeline by NTC srl, 2021
Bacterial Conjunctivitis - Pipeline by Takeda Pharmaceutical Co Ltd, 2021
Bacterial Conjunctivitis - Pipeline by TGV-Inhalonix Inc, 2021
Bacterial Conjunctivitis - Dormant Projects, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Bacterial Conjunctivitis, 2021
Number of Products under Development by Companies, 2021
Number of Products by Targets, 2021
Number of Products by Stage and Targets, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021